Non-Invasive Test May Transform Infant Meningitis Screening
A high-resolution ultrasound-based device demonstrated excellent accuracy in detecting elevated white blood cell (WBC) counts in cerebrospinal fluids, showing promise as a non-invasive screening tool for meningitis in neonates and infants with a permeable fontanel and potentially offering an alternative to lumbar puncture.
METHODOLOGY:
The diagnosis of meningitis requires an invasive lumbar puncture to collect cerebrospinal fluid for detecting elevated WBC counts; however, this procedure carries inherent risks and practical limitations.
Researchers conducted a prospective study across hospitals in Spain, Mozambique, and Morocco to validate the safety and accuracy of Neosonics — a non-invasive high-resolution ultrasound-based device that can detect signals from WBCs in the cerebrospinal fluid via the anterior fontanel — in neonates and infants younger than 24 months with suspected meningitis against the gold-standard techniques.
High-resolution images of the cerebrospinal fluid were captured and used to train a deep learning model that identified and classified cerebrospinal fluid patterns on the basis of lumbar puncture-confirmed WBC counts, with ≥ 30 cells/mm 3 defined as a case.
defined as a case. The accuracy of the trained algorithm was tested on 3782 high-resolution images of 76 patients.
TAKEAWAY:
The Neosonics device correctly identified 17 of 18 meningitis cases and 55 of 58 controls participants without meningitis, yielding a sensitivity of 94.4% and a specificity of 94.8%.
Overall, the device achieved an accuracy of 94.7% in detecting elevated WBC counts in the cerebrospinal fluid.
Misclassified participants either had low WBC counts or were microbiologically confirmed cases without elevated WBC counts.
IN PRACTICE:
"The non-invasive WBC counter, can lead to a more accurate indication for LP [lumbar puncture] and/or indications of treatment, resulting in better patient outcomes and in a reduction of the risk of long-term sequelae, along with a likely more cost-effective use of resources in all settings," the authors wrote.
SOURCE:
This study was led by Sara Ajanovic and Quique Bassat, ISGlobal, Barcelona, Spain, and Fernando Cabañas, Quirónsalud Madrid University Hospital, Madrid, Spain. It was published online on July 23, 2025, in Pediatric Research.
LIMITATIONS:
This study faced challenges in obtaining reliable gold-standard comparison results. The device's precision decreased in participants with thicker fontanels, and it misclassified three participants with very narrow cerebrospinal fluid spaces. Moreover, the image acquisition time was suboptimal.
DISCLOSURES:
This study was supported, in whole or in part, by the Gates Foundation in Mozambique and Morocco; funded by Instituto de Salud Carlos III and co-funded by the European Union in Spain; and funded by the Spanish Agency of Cooperation in Morocco. Five authors were employees of Kriba, the company developing Neosonics. One author and the ISGlobal Biomedical Data Science team disclosed receiving honoraria, training fees, and consulting fees from Kriba.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency
New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 6, 2025 /PRNewswire/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China's National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). This regulatory approval represents an important milestone in the management of infertility because, unlike laparoscopic assessment of tubal patency with use of a dye, HyCoSy is a non-invasive procedure, and, unlike traditional X-ray hysterosalpingography, HyCosy does not expose to radiation the genital tract of women in their reproductive years (4-6). "The NMPA approval of SonoVue® use with HyCoSy marks an important step in expanding access to non-invasive, radiation-free detection of tubal issues and uterine problems that often cause infertility in women," said Alberto Spinazzi, Chief Medical and Regulatory Officer, Bracco Group. "We strive to provide healthcare professionals in China with solutions that advance standards of care, reflecting our commitment to advancing diagnostic precision and improving the patient experience through contrast-enhanced ultrasound." "We are proud to support China's healthcare priorities through solutions like SonoVue® that may help address important diagnostic needs," said Valtero Canepa, Head of APAC, Bracco Imaging. "This new indication advances Bracco's role in delivering meaningful innovation in support of the Healthy China 2030 initiative, which prioritizes earlier detection, clinical precision, and broader access to reproductive health services." The high diagnostic performance of HyCoSy with SonoVue® has been confirmed by a recent systematic review and meta-analysis of 24 clinical studies (total of 1358 women with infertility and 2661 fallopian tubes). Using laparoscopic chromotubation dye test as the standard of truth for the assessment of fallopian tube patency, the pooled estimates of sensitivity, specificity, and accuracy of HyCoSy with SonoVue® were 93%, 90%, and 96%, respectively (1). Backed by over 20 years of clinical use, SonoVue® is the ultrasound contrast agent with the largest number of approved indications in the largest number of countries worldwide. The newly approved HyCoSy indication reinforces Bracco Imaging's commitment to expanding non-invasive, high-quality diagnostic tools aligned with evolving clinical standards and national health objectives in China and beyond. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med 2023; 42:7-15 Wang T, Dong T, Nie F. Clinical applications, advances, and future directions in hysterosalpingography. Front Med 2025; 12:1537506 Reproductive Health Branch of Chinese Preventive Medicine Association. Chinese Expert Consensus on Holistic Management of Tubal Factor Infertility (2023 edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics 2023; 39:318-324 Roy KK, Gajapathy SR, Rai R, Zangmo R, Das A, Singhal S. Assessment of Tubal Patency with Selective Chromopertubation at Office Hysteroscopy versus Modified Minilaparoscopy in Infertile Women. Gynecol Minim Invasive Ther 2021; 10:159-165 Perisinakis K, Damilakis J, Grammatikakis J, Theocharopoulos N, Gourtsoyiannis N. Radiogenic risks from hysterosalpingography. Eur Radiol 2003; 13:1522-1528 Sulieman A, Theodorou K, Vlychou M, Topaltzikis T, Roundas C, Fezoulidis I, Kappas C. Radiation dose optimisation and risk estimation to patients and staff during hysterosalpingography. Radiat Prot Dosimetry 2008;128:217-226 For additional information about Bracco's products, and for full prescribing information, please visit About Bracco ImagingBracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at Media Contacts: Bracco Press Contact:Carolina BargoniBracco Imaging, Communications 347 5397738 SOURCE Bracco Imaging
WebMD
41 minutes ago
- WebMD
From Lab to Pharmacy: The Journey to FDA Approval of Mepolizumab (Nucala) for COPD
In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science research. The FDA approval process for any new treatment is involved and careful, and requires testing in a lab, then testing in real people to be sure it's safe and effective. This testing allows researchers to more accurately say how well the drug works and answer questions such as: Do certain groups of patients benefit more from it than others? Are there any safety risks or concerns? The FDA uses the information from these trials to decide whether to approve the drug. Here's how that process evolved for mepolizumab. Step 1: Discovery and Development Mepolizumab first appeared on the medical treatment scene nearly 10 years ago as a biologic drug that doctors could prescribe for severe asthma. Biologics are drugs that researchers make in a lab that mimic biological chemicals in your body and either enhance or block the effect of that chemical. Mepolizumab blocks a chemical in your body called interleukin 5 (IL-5). IL-5 plays a key role in a specific type of inflammation – type 2 or TH2 inflammation – that results in higher levels of white blood cells called eosinophils. Eosinophils play a role in the body's immune response, especially in defending against parasites and allergens (substances that cause allergic reactions). "The simple thought was that if we blocked interleukin 5, which causes these eosinophils to rise and results in these inflammatory pathways, we could stop disease activity," says Frank Sciurba, MD, a pulmonologist and director of the Emphysema/COPD Research Center at the University of Pittsburgh Medical Center. With this idea in mind, researchers got to work conducting clinical trials for asthma. The FDA approved it to treat severe asthma (eosinophilic asthma) in 2015, and later for eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps. COPD is the fifth condition the FDA has approved mepolizumab to treat. Key Fact Biologics are drugs made in a lab that mimic biological chemicals in your body. They either enhance or block the effect of that chemical. Step 2: Testing in the Lab This step of the process involves giving the drug to animals in a laboratory. Researchers did this in the early studies of mepolizumab for asthma, so animal testing didn't have to be done again for the FDA to approve it for treating COPD. Instead, researchers were able to move directly to later phases of clinical trials in humans. Step 3: Testing in People Once researchers see that a drug is safe to use in animals, they begin trying it in humans. These clinical trials typically happen in phases: Phase I trials: Researchers use a small group of people (fewer than 100) to try the drug in humans for the first time. "Phase I trials are often just purely safety trials," says Sciurba. "These are eyes-wide-open, generally healthy volunteers that get paid just to see that they're safe." Phase II trials: The new drug or treatment is given to a larger group of people (100 to 300) to see if it works to treat the condition and look further at its safety. Researchers also work to figure out what dose of the drug makes the most sense. "It's the Goldilocks concept, especially in immune suppression," says Sciurba. "You have to hit the sweet spot. You don't want to suppress any more than you have to, but if you don't do it to some degree, you're not going to get the effect to get rid of these harmful pathways." Phase III trials: The new drug or treatment is given to large groups of people (1,000 to 3,000) to further show that it's effective, watch for side effects, and compare it to other treatments. Researchers knew that mepolizumab wouldn't be an effective treatment for every person with COPD. Only 20% to 40% of people living with COPD have the specific type of airway inflammation that mepolizumab addresses. "Mepolizumab is only tackling that subset of COPD – the bronchitis component that is being driven by eosinophilic inflammation," says Mario Castro, MD, MPH, principal investigator for the Kansas City site of the American Lung Association Asthma Clinical Research Centers (ACRC). Step 4: Checking by Experts Two phase III trials were important to the approval of mepolizumab. The first, METREX, tested the drug on 836 people in 2017. But the FDA ruled that this trial didn't show enough efficacy to approve mepolizumab to treat COPD. This "failure" helped researchers learn an important piece of information about whom the drug would work best for. "The most important mechanism of the drug is to prevent the activity of the eosinophils, and decrease the ability to attract eosinophils to areas of inflammation, so the higher the eosinophil level, the more likely that the drug is going to work," says Sciurba. This led to a phase III pivotal study called MATINEE. Researchers specifically recruited subjects with eosinophilic COPD who had an eosinophil count of 300 or greater. "In response to treatment with mepolizumab over a year, that population had a 20% decrease in exacerbations of their COPD," says Castro, who's also the division chief of pulmonary, critical care, and sleep medicine at the University of Kansas Health System. This outcome earned mepolizumab an FDA approval for treating COPD. Step 5: Watching Over Time After a drug is approved by the FDA and doctors can prescribe it to people, researchers continue to track its safety and make sure it's working as effectively as possible. Because clinical trials are a relatively small subset of all people with the condition the drug treats, this helps them see how the results look in much bigger groups of people. "Clinical trials typically have under a thousand people in them, so when you scale it up to 30,000 to 50,000 people, more rare events that could be causally related may start to peek out," says Sciurba. "So always there should be a level of observation, whether it's by the FDA or the medical community in general, to continue to monitor any therapies." The Bottom Line Mepolizumab is the second biologic the FDA has approved for treating COPD. The first, dupilumab (Dupixent), works in a similar way but targets different chemicals: IL-13 and IL-[1] 4. The FDA approved dupilumab for COPD in September 2024. Both drugs are very safe and well tolerated, and are only the tip of the iceberg, says Castro.
Yahoo
2 hours ago
- Yahoo
Talking therapy for back pain can help patients for up to three years
Talking therapies can reduce pain and disability among people with lower back pain, a new study suggests. And the benefit can be seen for up to three years after treatment, academics found. Psychotherapists use various talking therapies to help people to overcome stress, emotional and relationship problems or troublesome habits. For some, lower back pain will be a single incident which recovers on its own but most people with the condition will suffer long-term problems with unpredictable flare-ups. Most treatments for the condition have 'small to moderate' effects that do not last for a long period of time, experts said, The new study, published in the journal Lancet Rheumatology, focused on a type of psychotherapy called cognitive functional therapy (CFT) – a type of psychotherapy to 'address the causal mechanisms' of chronic lower back pain and help to change the way people think about and respond to pain. An international team of researchers, led by experts in Australia, wanted to examine whether CFT brought long-term benefits for patients with lower back pain. More than 1,000 patients from Australia with lower back pain were recruited to the study. A third were given 'usual care', a third were given CFT and the final third were given CFT plus another technique known as biofeedback, which tries to teach a person to control automatic body functions. People who received 'usual care' were given what their GP surgery recommended or what they chose. Some 300 people with an average age of 48 continued the study to the three-year follow-up point, split between each of the three groups. Researchers found that CFT, and CFT and biofeedback, were both more effective than usual care in reducing activity limitation caused by lower back pain. And they also were more effective for reducing pain intensity at three years. There were no significant differences among patients who did and did not use biofeedback techniques, prompting researchers to say the use of biofeedback 'did not add to effectiveness'. 'Treatment sessions of CFT produced sustained effects at three years for people with chronic disabling low back pain,' the researchers wrote. 'These long-term effects are novel and provide the opportunity to markedly reduce the effect of chronic back pain if the intervention can be widely implemented.' They added: 'CFT is the first treatment for chronic disabling low back pain with good evidence of large, long-term effects on disability. 'It offers a high-value, low-risk intervention with long-term benefits for patients with persistent, disabling low back pain.'
